Artivion announces presentation of new clinical data from nexus triomphe ide trial at the 105th american association for thoracic surgery (aats) annual meeting

30-day data from endospan's nexus triomphe ide trial demonstrate 63% reduction in major adverse event (mae) rate compared with reference performance goal atlanta , may 5, 2025 /prnewswire/ -- artivion, inc. (nyse: aort), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of new clinical data from endospan's nexus triomphe trial at the 105th american association for thoracic surgery (aats) annual meeting in seattle, washington. the data presented analyzed clinical outcomes across a 54-patient chronic aortic dissection statistical cohort at 30 days following treatment with nexus.
AORT Ratings Summary
AORT Quant Ranking